JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms

ABSTRACT: Background: Among the chronic myeloproliferative neoplasms (MPNs) not associated with BCR-ABL mutations are polycythemia vera, primary myelofibrosis, and essential thrombocythemia. These diseases are caused by mutations in genes, such as the JAK2, MPL, and CALR genes, which participate in...

Full description

Autores:
Giraldo Rincón, Ana Isabel
Naranjo Molina, Sara Carolina
Gómez Lopera, Natalia
Aguirre Acevedo, Daniel Camilo
Ucroz Benavidez, Andrea
Gálvez Cárdenas, Kenny Mauricio
Cuellar Ambrosí, Francisco
Torres Hernández, José Domingo
Ospina Ospina, Sigifredo
Palacio Rúa, Katherine Andrea
Gaviria Jaramillo, Lina María
Muñetón Peña, Carlos Mario
Vásquez Palacio, Gonzalo de Jesús
Tipo de recurso:
Article of investigation
Fecha de publicación:
2023
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
spa
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/42638
Acceso en línea:
https://hdl.handle.net/10495/42638
Palabra clave:
Calreticulina - genética
Calreticulin - genetics
Colombia
Mutación
Mutation
Trastornos Mieloproliferativos
Myeloproliferative Disorders
Policitemia Vera
Polycythemia Vera
Janus Quinasa 2
Janus Kinase 2
Receptores de Trombopoyetina
Receptors, Thrombopoietin
Mielofibrosis Primaria
Primary Myelofibrosis
Trombocitemia Esencial
Thrombocythemia, Essential
https://id.nlm.nih.gov/mesh/D037282
https://id.nlm.nih.gov/mesh/D003105
https://id.nlm.nih.gov/mesh/D009154
https://id.nlm.nih.gov/mesh/D009196
https://id.nlm.nih.gov/mesh/D011087
https://id.nlm.nih.gov/mesh/D053614
https://id.nlm.nih.gov/mesh/D053628
https://id.nlm.nih.gov/mesh/D055728
https://id.nlm.nih.gov/mesh/D013920
Rights
openAccess
License
https://creativecommons.org/licenses/by-nc-nd/4.0/
Description
Summary:ABSTRACT: Background: Among the chronic myeloproliferative neoplasms (MPNs) not associated with BCR-ABL mutations are polycythemia vera, primary myelofibrosis, and essential thrombocythemia. These diseases are caused by mutations in genes, such as the JAK2, MPL, and CALR genes, which participate in regulating the JAK-STAT signaling pathway. Objective: This study aimed to establish the frequencies of mutations in the JAK2, MPL, and CALR genes in a group of Colombian patients with a negative clinical diagnosis of BCR-ABL chronic myeloproliferative neoplasms. Methods: The JAK2 V617F and MPL W515K mutations and deletions or insertions in exon 9 of the CALR gene were analyzed in 52 Colombian patients with polycythemia vera, primary myelofibrosis, and essential thrombocythemia. Results: The JAK2V617F mutation was carried by 51.9% of the patients, the CALR mutation by 23%, and the MPL mutation by 3.8%; 23% were triple-negative for the mutations analyzed. In these neoplasms, 6 mutation types in CALR were identified, one of which has not been previously reported. Additionally, one patient presented a double mutation in both the CALR and JAK2 genes. Regarding the hematological results for the mutations, significant differences were found in the hemoglobin level, hematocrit level, and platelet count among the three neoplasms. Conclusion: Thus, this study demonstrates the importance of the molecular characterization of the JAK2, CALR and MPL mutations in Colombian patients (the genetic context of which remains unclear in the abovementioned neoplasms) to achieve an accurate diagnosis, a good prognosis, adequate management, and patient survival.